NOVO-B.CO - Novo Nordisk A/S
NEXT EARNINGS:
May 6, 2026
EPS Est: $5.18
|
Rev Est: $74.9B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
Market Cap:
1.08T
Volume:
19,587,886
Avg Volume:
8,006,674
52 Week Range:
240.4-675.2
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.40
Last Dividend:
$11.65
Exchange:
CPH
Country:
DK
Employees:
77,406
IPO Date:
2001-01-06
EPS (TTM):
23.06
P/E Ratio:
14.11
Revenue (TTM):
309.06B
Total Assets:
542.90B
Total Debt:
130.96B
Cash & Equiv:
26.46B
Rev Growth (5Y):
19.5%
EPS Growth (5Y):
20.6%
FCF Growth (5Y):
14.6%
ROCE:
41.2%
Debt/Equity:
0.67
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-04 | $5.98 | $5.82 | +2.7% | $79.1B | $76.2B | +3.9% |
| 2025-11-05 | $4.56 | $4.97 | -8.2% | $75.0B | $77.6B | -3.4% |
| 2025-08-06 | $6.00 | $5.98 | +0.3% | $76.9B | $77.5B | -0.8% |
| 2025-05-07 | $6.29 | $5.88 | +7.0% | $78.1B | $75.0B | +4.1% |
| 2025-02-05 | $6.35 | $6.16 | +3.1% | $85.7B | $80.3B | +6.8% |
| 2024-11-06 | $6.12 | $6.02 | +1.7% | $71.3B | $74.9B | -4.8% |
| 2024-08-07 | $4.49 | $4.66 | -3.6% | $68.1B | $67.3B | +1.2% |
| 2024-05-02 | $5.68 | $5.23 | +8.6% | $65.3B | $63.4B | +3.1% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 309.06B | 290.40B | 232.26B | 176.95B | 140.80B | 126.95B | 122.02B | 111.83B | 111.70B | 111.78B | 107.93B | 88.81B |
| Net Income | 102.43B | 100.99B | 83.68B | 55.52B | 47.76B | 42.14B | 38.95B | 38.63B | 38.13B | 37.92B | 34.86B | 26.48B |
| EPS | 23.06 | 22.67 | 18.67 | 12.26 | 10.40 | 9.03 | 8.21 | 7.98 | 7.71 | 7.50 | 6.78 | 5.05 |
| Total Assets | 542.90B | 465.80B | 314.49B | 241.26B | 194.51B | 144.92B | 125.61B | 110.77B | 102.36B | 97.54B | 91.80B | 77.06B |
| Total Debt | 130.96B | 102.79B | 27.01B | 25.78B | 26.64B | 10.36B | 4.48B | 515.00M | 1.69B | 229.00M | 1.07B | 720.00M |
| Cash & Equivalents | 26.46B | 15.65B | 14.39B | 12.65B | 10.72B | 12.76B | 15.47B | 15.64B | 18.85B | 18.69B | 16.92B | 14.40B |
| Operating Cash Flow | 119.10B | 120.97B | 108.91B | 78.89B | 55.00B | 51.95B | 46.78B | 44.62B | 41.17B | 48.31B | 38.29B | 31.69B |
| Free Cash Flow | 58.96B | 69.66B | 70.01B | 64.13B | 47.62B | 29.87B | 35.55B | 32.21B | 32.52B | 40.05B | 31.88B | 27.36B |
| FCF per Share | 13.27 | 15.64 | 15.62 | 14.16 | 10.36 | 6.40 | 7.49 | 6.66 | 6.57 | 7.91 | 6.20 | 5.22 |
| Book Value | 194.05B | 143.49B | 106.56B | 83.49B | 70.75B | 63.33B | 57.59B | 51.84B | 49.81B | 45.27B | 46.97B | 40.29B |
| Cash & ST Investments | 26.96B | 26.31B | 30.23B | 23.57B | 17.48B | 12.76B | 15.47B | 15.64B | 18.85B | 20.70B | 20.46B | 15.90B |
| ROC Equity | 0.53 | 0.70 | 0.79 | 0.67 | 0.68 | 0.67 | 0.68 | 0.75 | 0.77 | 0.84 | 0.74 | 0.66 |